Xenetic Biosciences, Inc. (XBIO)
Stock Price:
$0.870 USD
-0.031 (-3.45%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $0.880 +0.010 (1.14%) Oct 21, 5:28 PM
Key Info
| Market Cap |
5.48M |
| Revenue (ttm) |
186,742 |
| Net Income (ttm) |
-12.20M |
| Shares Out |
6.30M |
| EPS (ttm) |
-2.45 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 21, 2020 |
| Last Price |
$0.870 |
| Previous Close |
$0.901 |
| Change ($) |
-0.031 |
| Change (%) |
-3.45% |
| Day's Open |
0.890 |
| Day's Range |
0.860 - 0.910 |
| Day's Volume |
90,548 |
| 52-Week Range |
0.440 - 1.850 |
More Stats
| Market Cap |
5.48M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
Nov 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
6.30M |
| Float |
5.34M |
| EPS (basic) |
-0.27 |
| EPS (diluted) |
-2.45 |
| FCF / Share |
-1.02 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
452,653 |
| Short Ratio |
2.15 |
| Short % of Float |
8.48% |
| Beta |
2.41 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
29.34 |
| PB Ratio |
0.38 |
| Revenue |
186,742 |
| Operating Income |
-12.39M |
| Net Income |
-12.20M |
| Free Cash Flow |
-6.40M |
| Net Cash |
8.07M |
| Net Cash / Share |
1.28 |
| Gross Margin |
9.14% |
| Operating Margin |
-6,637.29% |
| Profit Margin |
-7,287.30% |
| FCF Margin |
-3,424.73% |
| ROA |
-28.86% |
| ROE |
-94.79% |
| ROIC |
-2,589.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$2.25*
(158.59% upside)
Low
2.00
Current: $0.870
High
2.50
Target: 2.25
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 0.02 | - | 7.59 | 3.00 | - | - | 1.00 | 0.29 |
| Revenue Growth | - | - | 152.83% | - | - | - | 240.6% | - |
| Gross Profit | 0.02 | - | 7.43 | 3.00 | - | - | 1.00 | 0.25 |
| Operating Income | -12.89 | -7.28 | -3.57 | -47.43 | -9.82 | -12.92 | -8.55 | -6.34 |
| Net Income | -12.78 | -7.30 | -3.60 | -54.21 | -12.51 | -14.31 | -8.58 | -6.33 |
| Shares Outstanding | 2.85 | 0.76 | 0.72 | 0.62 | 0.35 | 0.34 | 0.30 | 0.30 |
| Earnings Per Share | -6.33 | -9.66 | -4.92 | -94.08 | -35.52 | -43.57 | -27.72 | -19.80 |
| Operating Cash Flow | -6.40 | -6.46 | 1.49 | -8.79 | -5.30 | -12.68 | -6.05 | -6.26 |
| Capital Expenditures | - | 0.02 | -0.01 | -0.02 | 0.01 | -0.05 | -0.08 | -0.09 |
| Free Cash Flow | -6.40 | -6.44 | 1.48 | -8.80 | -5.29 | -12.74 | -6.13 | -6.35 |
| Cash & Equivalents | 10.37 | 0.64 | 5.60 | 4.11 | 0.20 | 2.57 | 4.91 | 11.14 |
| Total Debt | - | - | - | - | 4.05 | 0.40 | 0.68 | 0.68 |
| Net Cash / Debt | 10.37 | 0.64 | 5.60 | 4.11 | -3.85 | 2.18 | 4.22 | 10.45 |
| Assets | 21.55 | 14.43 | 19.16 | 20.97 | 16.91 | 16.32 | 19.47 | 25.37 |
| Liabilities | 4.33 | 4.52 | 4.86 | 4.80 | 10.30 | 5.84 | 6.85 | 4.59 |
| Book Value | 17.21 | 9.91 | 14.30 | 16.17 | 6.61 | 10.48 | 12.62 | 20.78 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Xenetic Biosciences, Inc. |
| Country |
United States |
| Employees |
4 |
| CEO |
Jeffrey F. Eisenberg |
Stock Information
| Ticker Symbol |
XBIO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: XBIO |
Description
Xenetic Biosciences, a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and novel oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.